Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Mar 14;40(3):252-254.
doi: 10.1016/j.ccell.2022.02.017.

Expanding the immunotherapy roadmap for hepatocellular carcinoma

Marina Baretti  1 , Amy K Kim  2 , Robert A Anders  3
Affiliations

Expanding the immunotherapy roadmap for hepatocellular carcinoma

Marina Baretti et al. Cancer Cell. .

Abstract

In a recent Lancet Oncology article, Yau et al. report the CheckMate 459 trial results. This is the first phase III trial comparing the single-agent anti-programmed death protein 1 (PD-1) therapy nivolumab to the tyrosine kinase inhibitor sorafenib for treatment-naive patients with advanced hepatocellular carcinoma.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests M.B. declares no competing interests. A.K.K. has received research funding from AstraZeneca and served on advisory boards for Exelixis and Eisai. R.A.A. receives research support from Bristol Myers Squibb, RAPT therapeutics, Stand up to Cancer, and the National Institutes of Health and serves on the advisory boards for Bristol Myers Squibb, Merck SD, and AstraZeneca.

Figures

Figure 1.
Figure 1.. Therapeutic options for hepatocellular carcinoma
(A) Summary of the recent landmark trials of first-line therapies in hepatocellular carcinoma (HCC). (B) Selection of first-line therapy in patients with advanced HCC.
See this image and copyright information in PMC

References

    1. Abou-Alfa GK, Lam Chan S, Kudo M, Lau G, Kelley RK, Furuse J, Sukeepaisarnjaroen W, Kang YK, Dao TV, De Toni EN, et al. (2022). Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA. J. Clin. Oncol. 40.
    1. El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M „ Hsu C„ Kim TY, Choo SP, Trojan J, Welling TH, et al. (2017). Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet 389, 2492–2502. 10.1016/S0140-6736(17)31046-2. - DOI - PMC - PubMed
    1. Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Pineros M, Znaor A, and Bray F (2019). Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int. J. Cancer 144, 1941–1953. 10.1002/ijc.31937. - DOI - PubMed
    1. Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, Kudo M, Breder V, Merle P, Kaseb AO, et al.; IMbrave150 Investigators (2020a). Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N. Engl. J. Med. 382, 1894–1905. 10.1056/NEJMOA1915745. - DOI - PubMed
    1. Finn RS, Ryoo BY, Merle P, Kudo M, Bouattour M, Lim HY, Breder V, Edeline J, Chao Y, Ogasawara S, et al.; KEYNOTE-240 investigators (2020b). Pembrolizumab As SecondLine Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial. J. Clin. Oncol. 38, 193–202. 10.1200/JCO.19.01307. - DOI - PubMed

Publication types

MeSH terms